DOCSLIB.ORG

Hyperlinked Region IX SOP for MWLCEMS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hyperlinked Region IX SOP for MWLCEMS 2 Region IX 2 0 0 STANDARD OPERATING PROCEDURES/ 1 1 STANDING MEDICAL ORDERS 9 9 McHenry Western Lake County EMS System Healthcare delivery requires structure (people, equipment, education) and process (policies, protocols, procedures) that, when integrated, produce a system (programs, organizations, cultures) that leads to optimal outcomes (patient survival and safety, quality, satisfaction). An effective system of care comprises all of these elements—structure, process, system, and patient outcomes—in a framework of continuous quality improvement (AHA, 2015). These protocols have been developed and approved through a collaborative process involving the Advocate Lutheran General; Greater Elgin Area, McHenry Western Lake County, Northwest Community, Amita Saint Joseph Hospital, and Southern Fox Valley EMS Systems to reduce variation in practice and establish a Region-wide System of care. They shall be used: as the written practice guidelines/pathways of care approved by the EMS Medical Directors (EMS MDs) to be initiated by System EMS personnel for off-line medical control. as the standing medical orders to be used by Emergency Communications Registered Nurses (ECRNs) when providing on-line medical control (OLMC). in medium to large scale multiple patient incidents, given that the usual and customary forms of communication are contraindicated as specified in the Region IX disaster plan. System members are authorized to implement these orders to their scope of practice. OLMC communication shall be established without endangering the patient. Under no circumstances shall emergency prehospital care be delayed while attempting to establish contact with a hospital. In the event that communications cannot be established, EMS personnel shall continue to provide care to the degree authorized by their license, these protocols, drugs/equipment available, and their scope of practice granted by the EMS MD in that System. Patient care is by nature unpredictable. In all circumstances, on line physicians have the latitude to deviate from these guidelines if it is believed that deviation is in the best interest of the patient. Such deviations should in no way detract from the high level of patient care expected from EMS personnel. If a patient situation is not covered by these standing orders, initiate Initial Medical or Initial Trauma Care and contact the nearest System hospital as soon as possible for a physician's instructions. John Pacini, D.O. EMS MD McHenry Western Lake County EMSS Intentionally left blank (inside cover) Region IX SOPS/SMOs: Effective 2019 Table of Contents GENERAL PATIENT MANAGEMENT Eye emergencies / Facial trauma 50 Introduction 1 Head trauma 51-52 EMS Scopes of Practice 2 Musculoskeletal trauma 53 General Patient Assessment/IMC 3-4 Spine trauma/Equipment removal guidelines 54-55 Pain management / Drug alternatives 5 Multiple Patient Incidents (NR) 56 OLMC Report/Handover Reports 6 START & JumpSTART 57 Withholding or Withdrawing Resuscitation 7-8 Hazardous Materials Incidents 58 Elderly patients 9 Chemical Agents 59 Extremely obese patients 10 Chempack Requests 60 RESPIRATORY Active Assailant Response 61-62 Airway obstruction 11 Widespread disease outbreak 63 Advanced airways/DAI 12 Abuse and Maltreatment: Domestic/Sexual/Elder 64 Allergic Reaction/Anaphylactic Shock 13 Trauma in pregnancy 65 Asthma/COPD 14 OB Pts w/ tracheostomy/laryngectomy (adult & peds) 15 Childbirth 66 Acute Resp. Disorders (FLU – Pulm. embolism) 16 Newborn and post-partum care 67 CARDIAC Delivery complications 68 Acute Coronary Syndromes/STEMI 17 Newborn resuscitation 69 Bradycardia with a Pulse 18 OB complications 70 Narrow QRS Complex Tachycardia 19 PEDS Wide Complex Tachycardia with a Pulse 20 Peds initial medical care 71 Cardiac Arrest Management (Adult & Peds) 21-22 Peds IMC – Circulation / perfusion / GCS 72 Heart Failure/Pulmonary Edema/Cardiogenic Shock 23 Peds Secondary assessment/sedation/VS 73-74 Left ventricular assist device 24 Special Healthcare needs 75 MEDICAL Peds Airway Adjuncts (NR) 76 Acute Abdominal/Flank Pain 25 Peds Respiratory: FBO; 77 Dialysis/Chronic Renal Failure 25 Peds Respiratory Arrest, SIDS, BRUE 78 Alcohol Intoxication/Withdrawal 26 Peds Allergic Rx ; Anaphylactic Shock 79 Altered Mental Status/Syncope & Presyncope 27 Peds Asthma 80 Drug Overdose/Poisoning 28-29 Peds Croup/ Epiglottitis / RSV/ Bronchiolitis 81 Carbon monoxide (HBO)/Cyanide exposure 30 Peds cardiac SOPs 83-84 Environmental emergencies: Cold related 31 Peds medical SOPs 85-88 Environmental emergencies: Submersion 32 Peds Seizure – Sepsis & Septic Shock 89-90 Environmental emergencies: Heat related 33 Peds ITC/Trauma score/Trauma SOPs/Abuse 91-93 Glucose/Diabetes Emergencies 34 APPENDIX 94-117 Hypertension/Hypertensive crisis 35 CPR: Quality criteria; peds defib table 94 Psych/Behavioral Emerg/Agitated/Violent Pts 36-37 Ketamine dose chart 95 Stroke – Assessment checklist 38-39 Drug appendix 96-106 Seizures 40 Peds Defib/Drug & adult fentanyl dose tables. 107-108 Shock - Septic 41 QT intervals; 12-lead changes in AMI 109 Shock – Hypovolemic 42 Medical abbreviations 110-111 TRAUMA (adult and peds) Differential of COPD/HF; CPAP ................................ 112 Initial trauma care (ITC)/GCS/RTS 43-44 Biologic, Nuclear, Incendiary & Chem agents ......... 113 Triage & transport criteria (table) 45 Bioterrorist Agents ..................................................... 114 Cardiac Arrest due to Trauma 46 Chemical Terrorism Agents ....................................... 115 Conducted electrical weapon (Taser) 46 Hospital Designations for Specialty Transports ........ 116 Burns 47-48 Pain scales ................................................................. 117 Dopamine Drug Chart 118 Chest trauma 49 Introduction Assumptions 1. All EMS personnel will function within their scope of practice as defined by the Illinois EMS Act, IDPH EMS Rules and Regulations promulgated by IDPH Division of EMS & HW Safety, and practice privileges authorized by the EMS MD of the System in which they are working. 2. These SOPs shall be evidence-based and revised as standards of practice or clinical practice guidelines change. They include recommendations from the National Association of EMS Physicians (National Model EMS Clinical Guidelines), Am Heart Association (CPR, ACLS/PALS), Am College of Surgeons (ATLS & PHTLS), Am College of Emergency Physicians (ITLS), Brain Trauma Foundation, Centers for Disease Control and Prevention, Dept. of Health & Human Services, EMS for Children; the National EMS Education Standards, Scope of Practice Model and EMS Core Content. 3. Italicized options may not be used in all Systems. Refer to the System-specific SOP documents. Those marked NR are non-region protocols that may or may not be adopted by each System or substituted with a System-specific document. 4. Levels of acuity: Definitions match Model of Clinical Practice of Emergency Medicine; in the Ntl EMS Core Content: Acuity level is essential for identifying care priorities in EMS setting. They are coded to NEMSIS standards and should be documented as such in the PCR/EHR. CRITICAL pts are TIME-SENSITIVE with black box notations in the SOPs. CRITICAL: Symptoms of a life threatening illness or injury with a high probability of mortality if immediate intervention is not begun to prevent further airway, respiratory, hemodynamic and/or neurologic instability. EMERGENT: Symptoms of illness or injury may progress in severity or result in complications w/ a high probability for morbidity if treatment is not begun quickly. These may be identified as time-sensitive on a case by case basis. LOWER ACUITY: Symptoms of an illness or injury that have a low probability of progression to more serious disease or development of complications. 5. Stable: Ability to maintain a steady state of equilibrium with VS that support adequate oxygenation, ventilation, perfusion, & mentation General guidelines 1. Abandonment: EMS personnel shall not knowingly abandon a patient. Abandonment is the unilateral termination of a health professional-patient relationship and/or the unreasonable discontinuation of care by the health care provider when there is still a need for continuing medical attention, contrary to the patient’s will, and/or without the patient’s knowledge. Abandonment for our purposes includes executing an inappropriate refusal, releasing a patient to a less qualified individual, or discontinuing needed medical monitoring before patient care is assumed by other professionals of equal or greater licensure than the level of care required by the patient. 2. Bus Accident: Refer to Region policy. 3. Consent: Decisional adults must consent to treatment. Consent must be informed or clearly implied via verbal agreement to the treatment or gestures indicating their desire for treatment. A patient's lack of refusal or physical resistance or withdrawal will be taken as consent. 4. Consent (Implied): Patients who are incapacitated so they cannot comply with the above provisions and do not exhibit the ability to make sound judgments, will be treated under implied consent. Patients who are obviously impaired with altered judgment who are unable to understand their decisions, have slurred speech, and/or ataxia; those suffering from mental illness; those who have made suicidal statements (to EMS personnel or persons physically present at the scene who will attest to the statements on a petition form) are to be treated under implied consent. They are not allowed to refuse treatment or transport. 5. Expanded
Load more

Recommended publications
  • Intraocular Pressure Rise After Phacoemulsification Prophylactic
    British Journal of Ophthalmology 1995; 79: 809-813 809 Intraocular pressure rise after phacoemulsification Br J Ophthalmol: first published as 10.1136/bjo.79.9.809 on 1 September 1995. Downloaded from with posterior chamber lens implantation: effect of prophylactic medication, wound closure, and surgeon's experience Thomas G Bomer, Wolf-Dietrich A Lagreze, Jens Funk Abstract pressure rises usually occur between 6 and 8 Aims-A prospective clinical trial was hours after surgery.6 carried out to evaluate the effect of Various antiglaucomatous agents have been prophylactic medication, the technique of used to prevent the intraocular pressure rise wound closure, and the surgeon's experi- after cataract extraction. Oral acetazolamide15 16 ence on the intraocular pressure rise after and topical timolol'6-19 lowered the pressure cataract extraction. rise in the early period after intracapsular and Methods-In 100 eyes, the intraocular extracapsular cataract extraction. Levobunolol pressure was measured before as well as proved to be superior to timolol 4-7 hours 2-4, 5-7, and 22-24 hours after phaco- after extracapsular cataract extraction.20 Apra- emulsification and posterior chamber lens clonidine lowered the intraocular pressure rise implantation. Each of 25 patients received after uncomplicated phacoemulsification21 and either 1% topical apraclonidine, 0.5%/o extracapsular cataract extraction22 23 when topical levobunolol, 500 mg oral acetazo- given 30 minutes to 1 hour before surgery, lamide, or placebo. Forty four eyes were whereas immediate postoperative treatment operated with sclerocorneal sutureless with apraclonidine was ineffective.22 24 Miotics tunnel and 56 eyes with corneoscleral are frequently used to promote miosis and incision and suture.
    [Show full text]
  • Brimonidine Tartrate; Brinzolamide
    Contains Nonbinding Recommendations Draft Guidance on Brimonidine Tartrate ; Brinzolamide This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Brimonidine tartrate; Brinzolamide Dosage Form; Route: Suspension/drops; ophthalmic Strength: 0.2%; 1% Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm, in vivo Strength: 0.2%; 1% Subjects: Males and females with chronic open angle glaucoma or ocular hypertension in both eyes. Additional comments: Specific recommendations are provided below. ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open angle glaucoma and ocular hypertension comparing the test product to the reference listed drug (RLD), each applied as one drop in both eyes three times daily at approximately 8:00 a.m., 4:00 p.m., and 10:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg
    OPTOMETRIC STUDY CENTER Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg. % Product Sizes Side Effects Warnings Reduction CHOLINERGIC AGENTS Direct Pilocarpine (generic) Pilocarpine 1%, 2%, 4% Increases trabecular outflow BID-QID/15-25% 15ml Headache, blurred vision, myopia, retinal detachment, bronchiole constriction, Angle closure, shortness of breath, retinal narrowing of angle detachment Indirect Phospholine Iodide (Pfizer) Echothiophate iodide 0.125% Increases trabecular outflow QD-BID/15-25% 5ml Same as above plus cataractogenic iris cysts in children, pupillary block, Same as above, plus avoid prior to any increased paralysis with succinylcholine general anesthetic procedure ALPHA-2 AGONISTS Alphagan P (Allergan) Brimonidine tartrate 0.1%, 0.15% with Purite Decreases aqueous production, increases BID-TID/up to 26% 5ml, 10ml, 15ml Dry mouth, hypotension, bradycardia, follicular conjunctivitis, ocular irritation, Monitor for shortness of breath, dizziness, preservative uveoscleral outflow pruritus, dermatitis, conjunctival blanching, eyelid retraction, mydriasis, drug ocular redness and itching, fatigue allergy Brimonidine tartrate Brimonidine tartrate 0.15%, 0.2% Same as above Same as above 5ml, 10ml Same as above Same as above (generic) Iopidine (Novartis) Apraclonidine 0.5% Decreases aqueous production BID-TID/up to 25% 5ml, 10ml Same as above but higher drug allergy (40%) Same as above BETA-BLOCKERS Non-selective Betagan (Allergan) Levobunolol 0.25%, 0.5% Decreases
    [Show full text]
  • NEW ZEALAND DATA SHEET 1. PRODUCT NAME IOPIDINE® (Apraclonidine Hydrochloride) Eye Drops 0.5%
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME IOPIDINE® (apraclonidine hydrochloride) Eye Drops 0.5%. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each mL of Iopidine Eye Drops 0.5% contains apraclonidine hydrochloride 5.75 mg, equivalent to apraclonidine base 5 mg. Excipient with known effect Benzalkonium chloride 0.1 mg per 1 mL as a preservative. For the full list of excipients, see section 6.1. 2. PHARMACEUTICAL FORM Eye drops, solution, sterile, isotonic. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications Iopidine Eye Drops 0.5% are indicated for short-term adjunctive therapy in patients on maximally tolerated medical therapy who require additional IOP reduction. Patients on maximally tolerated medical therapy who are treated with Iopidine Eye Drops 0.5% to delay surgery should have frequent follow up examinations and treatment should be discontinued if the intraocular pressure rises significantly. The addition of Iopidine Eye Drops 0.5% to patients already using two aqueous suppressing drugs (i.e. beta-blocker plus carbonic anhydrase inhibitor) as part of their maximally tolerated medical therapy may not provide additional benefit. This is because apraclonidine is an aqueous-suppressing drug and the addition of a third aqueous suppressant may not significantly reduce IOP. The IOP-lowering efficacy of Iopidine Eye Drops 0.5% diminishes over time in some patients. This loss of effect, or tachyphylaxis, appears to be an individual occurrence with a variable time of onset and should be closely monitored. The benefit for most patients is less than one month. 4.2. Dose and method of administration Dose One drop of Iopidine Eye Drops 0.5% should be instilled into the affected eye(s) three times per day.
    [Show full text]
  • 0Bcore Safety Profile
    Core Safety Profile Active substance: Levobunolol Pharmaceutical form(s)/strength: Eye drops solution/ 0,1%; 0,25%; 0,5%; 0,5% UD P-RMS: CZ/H/PSUR/0006/001 Date of FAR: 26.05.2009 4.2 Posology and method of administration Adults (including the elderly) Country specific posology and method of administration to be included. Children /.../ is not recommended for use in children due to lack of safety and efficacy data. If required, /.../ may be used with other agents to lower intra-ocular pressure. The use of two topical beta-adrenergic blocking agents is not recommended (see section 4.4). Intraocular pressure should be measured approximately four weeks after starting treatment with /.../ as a return to normal ocular pressure can take a few weeks. As with any eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac is compressed at the medial canthus (punctual occlusion) for one minute. This should be performed immediately following the instillation of each drop. Transfer from other beta-blocking treatment When another beta blocking agent is being used treatment must be discontinued after a full day of therapy. Start treatment with /.../ the next day with X drop of /.../ topically applied into the conjunctival sac in the affected eye(s). If /.../ is to replace a combination of anti-glaucoma products, only a single product should be removed at a time. Use in renal and hepatic impairment Levobunolol hydrochloride has not been studied in patients with hepatic or renal impairment. Therefore, caution should be used in treating such patients (see section 4.4).
    [Show full text]
  • BETA RECEPTOR BLOCKERS MC Objective
    Jack DeRuiter, Principles of Drug Action 2, Fall 2000 ADRENERGIC RECEPTOR ANTAGONISTS: BETA RECEPTOR BLOCKERS MC Objective: Describe the development of beta antagonists ("beta blockers") from the agonist norepinephrine (NE): HO H NH2 NE Alpha- and Beta-receptor agonist HO OH H H HO CH N 3 H Isoproterenol CH3 Selective beta-receptor agonist HO OH H H HO CH N 3 H Dichloroisoproterenol CH3 Partial beta-receptor agonist/antagonist Cl Cl H H HO CH N 3 Pronethalol H Beta-receptor antagonist, CH 3 low activity and toxic CH3 O N H Propranolol CH3 OH H Potent beta-antagonist No beta-receptor subtype selectivity CH3 CH3 O N H O N H CH CH OH H 3 OH H 3 Metoprolol N Beta-1-receptor H Pindolol O subtype selectivity Partial beta-agonist CH3 No beta-receptor subtype selectivity HO H H N H CH3 HO Labetolol O NH2 Dual alpha- and beta-antagonst 1 Jack DeRuiter, Principles of Drug Action 2, Fall 2000 MC Objective: Based on their structures, would the beta-blockers be expected to be relatively receptor selective? YES. They do not produce significant blockade of alpha- adrenergic receptors (alpha-1 or alpha-2), histamine receptors, muscarinic receptors or dopamine receptors. MC/PC Objective: Identify which beta blockers are classified as "non-selective": · The “non-selective" classification refers to those beta-blockers capable of blocking BOTH beta-1 and beta-2 receptors with equivalent efficacy. These drugs DO NOT have clinically significant affinity for other neurotransmitter receptors (alpha, dopamine, histamine, acetylcholine, etc.). · ALL of these beta-blockers (except satolol) consist of an aryloxypropanolamine side chain linked to an aromatic or “heteroaromatic” ring which is “ortho” substituted.
    [Show full text]
  • Antiglaucoma Compositions Containing Combinations of Alpha-2 Agonists and Beta-Blockers
    ~" ' MM II II II MM II II II Ml II II I II J European Patent Office _ _ _ © Publication number: 0 365 662 B1 Office europeen* des.. brevets , © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 09.03.94 © Int. CI.5: A61 K 31/47 © Application number: 89905874.7 @ Date of filing: 26.04.89 © International application number: PCT/US89/01994 © International publication number: WO 89/10126 (02.11.89 89/26) (54) ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF ALPHA-2 AGONISTS AND BETA-BLOCKERS. ® Priority: 26.04.88 US 186504 1075-1078 @ Date of publication of application: J. of Cardiovascular Pharmacology, vol. 2, 02.05.90 Bulletin 90/18 suppl. 1, 1980, S. 21-28 © Publication of the grant of the patent: © Proprietor: ALCON LABORATORIES INC 09.03.94 Bulletin 94/10 6201 South Freeway Ft. Worth, TX 76134(US) © Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE @ Inventor: DE SANTIS, Louis, M. 2316 Wlnton Terrace West © References cited: Fort Worth, TX 761 09(US) US-A- 4 455 317 US-A- 4 515 800 © Representative: Jump, Timothy John Simon et AM A DRUG EVALUATION, 2nd ed., 1973; al "Agent used to treat Glaucoma", pp. 675-686. Venner Shipley & Co. 20 Little Britain GLAUCOMA, vol. 1, no. 1, February 1979; London EC1A 7DH (GB) 00 S.SUGAR, pp. 9-15. CM CO Ophthalmology, vol. 96, no. 1, 1989, p. 3-7 CO m Ophthalmology, vol. 98, no. 7, 1991, p. CO 00 Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted.
    [Show full text]
  • REMEDY for GLAUCOMA COMPRISING Rho KINASE INHIBITOR and -BLOCKER
    Europäisches Patentamt *EP001568382A1* (19) European Patent Office Office européen des brevets (11) EP 1 568 382 A1 (12) EUROPEAN PATENT APPLICATION published in accordance with Art. 158(3) EPC (43) Date of publication: (51) Int Cl.7: A61K 45/06, A61K 31/138, 31.08.2005 Bulletin 2005/35 A61K 31/343, A61K 31/353, A61K 31/437, A61K 31/4409, (21) Application number: 03772800.3 A61K 31/4412, A61K 31/496, (22) Date of filing: 17.11.2003 A61K 31/5377, A61K 31/551, A61P 27/06, A61P 43/00 (86) International application number: PCT/JP2003/014559 (87) International publication number: WO 2004/045644 (03.06.2004 Gazette 2004/23) (84) Designated Contracting States: • NAKAJIMA, Tadashi AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Ikoma-shi, Nara 630-0101 (JP) HU IE IT LI LU MC NL PT RO SE SI SK TR • MATSUGI, Takeshi Designated Extension States: Ikoma-shi, Nara 630-0101 (JP) AL LT LV MK • HARA, Hideaki Ikoma-shi, Nara 630-0101 (JP) (30) Priority: 18.11.2002 JP 2002333213 (74) Representative: Peaucelle, Chantal et al (71) Applicant: SANTEN PHARMACEUTICAL CO., Cabinet Armengaud Ainé LTD. 3, avenue Bugeaud Osaka 533-8651 (JP) 75116 Paris (FR) (72) Inventors: • HATANO, Masakazu Ikoma-shi, Nara 630-0101 (JP) (54) REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND &bgr;-BLOCKER (57) A subject of the present invention is to find utility of a co mbination of a Rho kinase inhibitor having a novel action and a β-blocker as a therapeutic agent for glau- coma.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Step Therapy Criteria Standard
    ANTIDEPRESSANTS, SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS PDP EGWP STANDARD Products Affected Step 1: bupropion hcl 100 mg tablet fluvoxamine er 100 mg capsule,extended bupropion hcl 75 mg tablet release 24 hr bupropion hcl sr 100 mg tablet,12 hr fluvoxamine er 150 mg capsule,extended sustained-release release 24 hr bupropion hcl sr 150 mg tablet,12 hr mirtazapine 15 mg disintegrating tablet sustained-release mirtazapine 15 mg tablet bupropion hcl sr 200 mg tablet,12 hr mirtazapine 30 mg disintegrating tablet sustained-release mirtazapine 30 mg tablet bupropion hcl xl 150 mg 24 hr tablet, mirtazapine 45 mg disintegrating tablet extended release mirtazapine 45 mg tablet bupropion hcl xl 300 mg 24 hr tablet, mirtazapine 7.5 mg tablet extended release paroxetine 10 mg tablet citalopram 10 mg tablet paroxetine 20 mg tablet citalopram 10 mg/5 ml oral solution paroxetine 30 mg tablet citalopram 20 mg tablet paroxetine 40 mg tablet citalopram 40 mg tablet paroxetine er 12.5 mg tablet,extended duloxetine 20 mg capsule,delayed release release 24 hr duloxetine 30 mg capsule,delayed release paroxetine er 25 mg tablet,extended duloxetine 40 mg capsule,delayed release release 24 hr duloxetine 60 mg capsule,delayed release paroxetine er 37.5 mg tablet,extended escitalopram 10 mg tablet release 24 hr escitalopram 20 mg tablet sertraline 100 mg tablet escitalopram 5 mg tablet sertraline 20 mg/ml oral concentrate escitalopram 5 mg/5 ml oral solution sertraline 25 mg tablet fluoxetine (pmdd) 10 mg tablet sertraline
    [Show full text]